Cantor Fitzgerald Estimates MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical company will post earnings of ($9.20) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.55) per share.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.94) by $2.02. The firm had revenue of $62.18 million for the quarter, compared to analysts’ expectations of $34.60 million. During the same period in the prior year, the company earned ($5.34) EPS.

A number of other research analysts have also recently commented on MDGL. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a research report on Saturday, October 12th. Oppenheimer dropped their price target on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. B. Riley increased their price objective on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. UBS Group lifted their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, HC Wainwright upped their price target on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $351.67.

Madrigal Pharmaceuticals Stock Up 5.7 %

Shares of NASDAQ MDGL opened at $324.71 on Wednesday. Madrigal Pharmaceuticals has a one year low of $168.25 and a one year high of $368.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The business’s fifty day moving average price is $312.63 and its 200-day moving average price is $273.07. The stock has a market capitalization of $7.08 billion, a PE ratio of -12.95 and a beta of -0.36.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MDGL. KBC Group NV raised its position in shares of Madrigal Pharmaceuticals by 73.5% in the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock worth $188,000 after acquiring an additional 258 shares in the last quarter. Miracle Mile Advisors LLC purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter worth $216,000. Franklin Resources Inc. raised its holdings in Madrigal Pharmaceuticals by 8.0% in the third quarter. Franklin Resources Inc. now owns 1,383 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 103 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Madrigal Pharmaceuticals by 12.7% in the third quarter. Sanctuary Advisors LLC now owns 1,185 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 134 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Madrigal Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 405,655 shares of the biopharmaceutical company’s stock valued at $86,104,000 after buying an additional 5,801 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Richard S. Levy sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the transaction, the director now directly owns 11,012 shares of the company’s stock, valued at approximately $3,313,951.28. The trade was a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $461,789.49. Following the transaction, the chief marketing officer now owns 457,310 shares of the company’s stock, valued at approximately $125,033,127.10. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,408 shares of company stock worth $4,489,207. 22.80% of the stock is currently owned by insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.